Comparison of the effect of gonadotropin-releasing hormone agonist dosage in girls with central precocious puberty
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: There are no definite guidelines on the optimal dosage of gonadotropin-releasing hormone (GnRH) agonist for treatment of central precocious puberty (CPP). We compared growth outcomes of GnRH agonist at different dosages in girls with idiopathic CPP to assess the optimal dosage. Methods: This retrospective study included 86 girls with idiopathic CPP who had been treated with GnRH agonist for at least one year and had attained their final adult height. Leuprolide was given as fixed dosage (3.75 mg every 4 weeks in body weight >20 kg, n=72) or weight-based dosage (60–85 μg/kg every 4 weeks, n=14). We compared suppression of advanced puberty and treatment response between the 2 groups. Results: Peak estradiol and luteinizing hormone and bone age (BA)/chronological age after injection of GnRH agonist were effectively suppressed in both groups. In both groups, the height standard deviation score (SDS) for BA increased after treatment. Final adult height (FAH) (fixed dosage group,160.8±4.1 cm and weight-based dosage group, 161.2±4.4 cm) was significantly higher than the initial predicted adult height (PAH) (155.5±3.3 and 156.1±3.6 cm, respectively) (both P<0.001) and similar to midparental height (159.8±3.3 and 160.6±3.7 cm, respectively). There were no differences in gain in height SDS for BA and gain in height (FAH-PAH at the start) between the 2 groups. Conclusion: There were no differences in treatment outcome between fixed dosage (3.75 mg/4 wk) and weight-based dosage (60–85 μg/kg/4wk) of GnRH agonist. Therefore, a fixed dosage of GnRH agonist can be used more conveniently for CPP treatment without growth oversuppression.
Abstract
Purpose: There are no definite guidelines on the optimal dosage of gonadotropin-releasing hormone (GnRH) agonist for treatment of central precocious puberty (CPP). We compared growth outcomes of GnRH agonist at different dosages in girls with idiopathic CPP to assess the optimal dosage. Methods: This retrospective study included 86 girls with idiopathic CPP who had been treated with GnRH agonist for at least one year and had attained their final adult height. Leuprolide was given as fixed dosage (3.75 mg every 4 weeks in body weight >20 kg, n=72) or weight-based dosage (60–85 μg/kg every 4 weeks, n=14). We compared suppression of advanced puberty and treatment response between the 2 groups. Results: Peak estradiol and luteinizing hormone and bone age (BA)/chronological age after injection of GnRH agonist were effectively suppressed in both groups. In both groups, the height standard deviation score (SDS) for BA increased after treatment. Final adult height (FAH) (fixed dosage group,160.8±4.1 cm and weight-based dosage group, 161.2±4.4 cm) was significantly higher than the initial predicted adult height (PAH) (155.5±3.3 and 156.1±3.6 cm, respectively) (both P<0.001) and similar to midparental height (159.8±3.3 and 160.6±3.7 cm, respectively). There were no differences in gain in height SDS for BA and gain in height (FAH-PAH at the start) between the 2 groups. Conclusion: There were no differences in treatment outcome between fixed dosage (3.75 mg/4 wk) and weight-based dosage (60–85 μg/kg/4wk) of GnRH agonist. Therefore, a fixed dosage of GnRH agonist can be used more conveniently for CPP treatment without growth oversuppression.
참고문헌 (19)
- Styne DM, "Williams textbook of endocrinology", pp.1054~1201 (2011), Saunders Elsevier
- Kim YJ, "Incidence and prevalence of central precocious puberty in Korea : an epidemiologic study based on a national database", J Pediatr, 208, pp.221~228 (2019)
- De Sanctis V, "Etiology of central precocious puberty in males : the results of the Italian Study Group for Physiopathology of Puberty", J Pediatr Endocrinol Metab, 13(Suppl 1), pp.687~693 (2000)
- Cisternino M, "Etiology and age incidence of precocious puberty in girls : a multicentric study", J Pediatr Endocrinol Metab, 13(Suppl 1), pp.695~701 (2000)
- Huynh Quynh Thi Vu, "Pathological brain lesions in girls with central precocious puberty at initial diagnosis in Southern Vietnam", Annals of Pediatric Endocrinology & Metabolism, 27(2), pp.105~112 (2022), 대한소아내분비학회[DOI]
- Carel JC, "Clinical practice. Precocious puberty", N Engl J Med, 358, pp.2366~2377 (2008)
- Bangalore Krishna K, "Use of gonadotropin-releasing hormone analogs in children : update by an International Consortium", Horm Res Paediatr, 91, pp.357~372 (2019)
- 김호성, "Clinical application of gonadotropin-releasing hormone analogs in children and adolescents", Clinical and Experimental Pediatrics, 53(3), pp.294~299 (2010), 대한소아청소년과학회
- Jeon Min Jin, "Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty", Annals of Pediatric Endocrinology & Metabolism, 26(3), pp.171~177 (2021), 대한소아내분비학회[DOI]
- Vurallı D, "Treatment with depot leuprolide acetate in girls with idiopathic precocious puberty : what parameter should be used in deciding on the initial dose?", J Clin Res Pediatr Endocrinol, 12, pp.37~44 (2020)
- Lee PA, "Efficacy of leuprolide acetate 1-month depot for central precocious puberty(CPP) : growth outcomes during a prospective, longitudinal study", Int J Pediatr Endocrinol, 2011, pp.7~ (2011)
- Carel JC, "Consensus statement on the use of gonadotropin-releasing hormone analogs in children", Pediatrics, 123, pp.e752~e762 (2009)
- Tanaka T, "A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group", Endocrinol Jpn, 38, pp.369~376 (1991)
- 심계식, "중추성 성조숙증 및 조기 사춘기 여아에서 성선자극호르몬 방출호르몬작용제의 용량에 따른 사춘기 억제 효과 비교", Clinical and Experimental Pediatrics, 51(6), pp.634~639 (2008), 대한소아청소년과학회
- 진혜영, "진성 성조숙증에서 GnRH agonist의 용량에 따른 최종예측 성인신장 개선 효과의 차이에 관한 연구", Annals of Pediatric Endocrinology & Metabolism, 15(2), pp.120~125 (2010), 대한소아내분비학회
- Siti Nadirah Ab Rahim, "Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review", Annals of Pediatric Endocrinology & Metabolism, 25(3), pp.152~155 (2020), 대한소아내분비학회[DOI]
- Greulich WW, "Radiographic atlas of skeletal development of the hand and wrist" (1959), Stanford University Press
- Bayley N, "Tables for predicting adult height from skeletal age : revised for use with the Greulich-Pyle hand standards", J Pediatr, 40, pp.423~441 (1952)
- Korea Center for Disease Control and Prevention, "2007 Korean children and adolescents growth standard (commentary for the development of 2007 growth chart)" (2007), Division of Chronic Disease Surveillance